Fresenius Medical Care Corporation (NYSE:FMS)‘s stock had its “buy” rating reiterated by stock analysts at DZ Bank AG in a research note issued on Monday.

A number of other equities analysts also recently weighed in on FMS. UBS AG reaffirmed a “sell” rating on shares of Fresenius Medical Care Corporation in a research note on Tuesday, July 4th. Royal Bank Of Canada reissued a “neutral” rating on shares of Fresenius Medical Care Corporation in a research report on Tuesday, August 1st. BidaskClub lowered shares of Fresenius Medical Care Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Zacks Investment Research raised shares of Fresenius Medical Care Corporation from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research report on Tuesday, July 11th. Finally, Nord/LB reissued a “buy” rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $48.67.

Fresenius Medical Care Corporation (NYSE:FMS) traded down 1.16% during mid-day trading on Monday, reaching $45.91. 205,936 shares of the company traded hands. The stock has a market capitalization of $28.18 billion, a PE ratio of 20.36 and a beta of 0.47. The stock has a 50-day moving average of $48.44 and a 200 day moving average of $44.54. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22.

Fresenius Medical Care Corporation (NYSE:FMS) last posted its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.53 by $0.05. The company had revenue of $4.47 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.96 EPS. Equities research analysts expect that Fresenius Medical Care Corporation will post $2.32 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Fresenius Medical Care Corporation (NYSE:FMS) Stock Rating Reaffirmed by DZ Bank AG” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/07/fresenius-medical-care-corporation-nysefms-stock-rating-reaffirmed-by-dz-bank-ag.html.

Several large investors have recently added to or reduced their stakes in the company. UBS Asset Management Americas Inc. acquired a new position in Fresenius Medical Care Corporation during the fourth quarter worth approximately $1,133,000. World Asset Management Inc boosted its position in Fresenius Medical Care Corporation by 1.0% in the first quarter. World Asset Management Inc now owns 38,273 shares of the company’s stock worth $1,612,000 after buying an additional 369 shares in the last quarter. Intrust Bank NA boosted its position in Fresenius Medical Care Corporation by 0.8% in the first quarter. Intrust Bank NA now owns 13,219 shares of the company’s stock worth $557,000 after buying an additional 99 shares in the last quarter. Cambiar Investors LLC boosted its position in Fresenius Medical Care Corporation by 8.1% in the first quarter. Cambiar Investors LLC now owns 2,516,416 shares of the company’s stock worth $106,017,000 after buying an additional 188,019 shares in the last quarter. Finally, Wrapmanager Inc. boosted its position in Fresenius Medical Care Corporation by 3.5% in the first quarter. Wrapmanager Inc. now owns 7,222 shares of the company’s stock worth $304,000 after buying an additional 244 shares in the last quarter. 2.84% of the stock is owned by institutional investors.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.